- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03301870
A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers
January 14, 2019 updated by: UNION therapeutics
A Single-Site Study To Evaluate The Irritation Potential Of Topically Applied ATx201 In Healthy Human Volunteers on Intact and Abraded Skin
This is a Phase I single-site study to evaluate the irritation potential of topically applied ATx201 GEL, 2% and 4%, along with positive and negative control and placebo control (ATx201 GEL Placebo), in healthy human subjects on intact and abraded skin.
Approximately thirty-six (36) healthy adult subjects will receive all the test articles to provide for 30 subjects to complete the study.
The test articles will be applied to the upper back of the subjects during the study, and the placement of the test articles will be randomized.
Abraded skin will be induced using sequential tape stripping.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Springfield, Missouri, United States, 65802
- Bio-Kinetic Clinical Applications, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Judged by the Investigator to have no health conditions that would impact the safety of the subject during participation.
- Body Mass Index (BMI) to be no less than 19.0 and no greater than 36.0 kg/m² (inclusive).
- Demonstrates a Fitzpatrick skin score of I - IV
- Female subjects must agree to use a medically acceptable contraceptive method
- Willing to refrain from excessive consumption of sodium (> 2,400 mg/day or > 1 teaspoon equivalent/day) in food or beverage 48 hours prior to Day 1 through EOS Visit.
- Willing to shower using the same non-medicated soap/cleansers, and abstain from excessive sun exposure (including tanning salons) from the Screening Visit through EOS Visit.
Exclusion Criteria:
- any clinical investigational product within 30 days prior to Day 1 through EOS Visit
- recent or current medical condition that, in the opinion of the Investigator, might significantly affect an immunological response to topical ATx201 or compromise the safety of the subject.
- history of diabetes mellitus, clinically significant asthma (acceptable if no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or circulatory disease.
- use of any medication on a regular basis within 14 days prior to Day 1 through EOS that could change peripheral blood flow, with the exception of any prescribed birth control method or hormone replacement therapy.
- use of any oral, nasal or topical corticosteroids, or oral or topical retinoids (other than Vitamin A at normal dietary amounts) within 14 days prior to the Screening Visit through EOS Visit.
- intending to start, stop, or change the dose of any prescription or over-the-counter (OTC) medication within 48 hours prior to Day 1 through EOS Visit.
- use of any prescription or OTC topical medications on the upper back within 30 days prior to Day 1 through EOS Visit.
- history of sensitivity/allergy to any ingredients found in the ATx201 formulation or has a history of adverse reactions to topical medications.
- significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
- history of significant skin conditions or disorders such as psoriasis, atopic dermatitis, etc.
- history of significant dermatologic cancers, for example, melanoma or squamous cell carcinoma.
- displays an obvious difference in skin color on the upper back or the presence of a skin anomaly such as a recent sunburn, scratch, scar tissue, tattoo, or coloration that would interfere with placement of test sites, their assessment, and their potential response to the study drug or that could compromise the safety of the subject.
- smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1 through EOS Visit.
- female who is pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
- history of drug or alcohol addiction or abuse within the past year.
- caffeine intake greater than 500 mg per day (for example, 1 cup of coffee contains approximately 85 mg of caffeine, tea approximately 25 mg, soft drinks up to 115 mg, energy drinks 90 - 422 mg).
- unwilling to abstain from energy drinks, alcohol, and excessive caffeine (> 500 mg/day) for 48 hours prior to Day 1 through EOS Visit.
- reports having donated blood or plasma within 48 hours prior to Day 1 through EOS Visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATx201 GEL, 2% - intact skin
ATx201 GEL, 2% applied intact skin
|
2% active gel
|
Experimental: ATx201 GEL, 4% - intact skin
ATx201 GEL, 4% applied to intact skin
|
4% active gel
|
Experimental: ATx201 GEL, 2% - abraded skin
ATx201 GEL, 2% applied to abraded skin
|
2% active gel
|
Experimental: ATx201 GEL, 4% - abraded skin
ATx201 GEL, 4% applied to abraded skin
|
4% active gel
|
Placebo Comparator: ATx201 GEL Placebo - intact skin
ATx201 GEL Placebo applied to intact skin
|
matching placebo gel
|
Placebo Comparator: ATx201 GEL Placebo - abraded skin
ATx201 GEL Placebo applied to abraded skin
|
matching placebo gel
|
Active Comparator: Negative Irritant Control - intact skin
Negative (low) Irritant Control applied to intact skin
|
Water for Injection, USP
|
Active Comparator: Negative Irritant Control - abraded skin
Negative (low) Irritant Control applied to abraded skin
|
Water for Injection, USP
|
Active Comparator: Positive Irritant Control - intact skin
Positive (high) Irritant Control applied to intact skin
|
Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Irritation Scores
Time Frame: 21 days
|
the sum of the combined Dermal response and Other Effects Score
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of combined Dermal response and Other Effects Score >=3
Time Frame: 21 days
|
Total number of days with a combined Dermal Response and Other Effects score of 3 or more for each test article
|
21 days
|
Incidence of Test Article Discontunation
Time Frame: 21 days
|
Number of subjects, by test article, where a test article was discontinued due to an unacceptable degree of irritation, or who experienced symptomatic intolerable irritation
|
21 days
|
Time to test article discontinuation
Time Frame: 21 days
|
Number of days until sufficient irritation occurred to preclude repeat application to the same site, or who experienced symptomatic intolerable irritation
|
21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Philippe Prokocimer, MD, Sponsor CMO
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 4, 2017
Primary Completion (Actual)
November 6, 2017
Study Completion (Actual)
November 6, 2017
Study Registration Dates
First Submitted
September 29, 2017
First Submitted That Met QC Criteria
September 29, 2017
First Posted (Actual)
October 4, 2017
Study Record Updates
Last Update Posted (Actual)
January 16, 2019
Last Update Submitted That Met QC Criteria
January 14, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- ATx201-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritation Potential of Topic Agent
-
Inflamax Research IncorporatedCompletedBioequivalence - Irritation and Sensitization Potential of Transdermal PatchUnited States, Canada
-
Oxytone Bioscience BVWithdrawnHealthy Women of Child Bearing Potential
-
Chattem, Inc.CompletedTolerability | Adhesiveness | Dermal Irritation | Effects of HeatUnited States
-
Shenyang Northern HospitalNot yet recruitingSmoking Cessation | ACS | Clonal Hematopoiesis of Indeterminate PotentialChina
-
Chattem, Inc.CompletedTolerability | Adhesiveness | Dermal Irritation | Effects of HeatUnited States
-
Food and Nutrition Research Institute, PhilippinesMahidol University; International Atomic Energy AgencyNot yet recruitingHealthy Women of Child Bearing PotentialPhilippines
-
University of ZurichCompletedRegeneration Potential of Healthy Old Men in Terms of Satellite Cell ActivationSwitzerland
-
Rippe Lifestyle InstituteCompletedConditions: None. Focus: Understanding the Obesogenic Potential of Fructose Containing SugarsUnited States
-
Jazz PharmaceuticalsCompleted
-
U.S. Army Medical Research and Development CommandCompletedTreatment Against the Lethal Effects of Nerve Agent IntoxicationUnited States
Clinical Trials on ATx201 Gel 2%
-
UNION therapeuticsCompleted
-
UNION therapeuticsCompleted
-
UNION therapeuticsCompletedAtopic DermatitisCanada
-
UNION therapeuticsCompletedAtopic DermatitisBulgaria, Denmark, Poland
-
UNION therapeuticsCompleted
-
Sol-Gel Technologies, Ltd.TerminatedBasal Cell Nevus SyndromeUnited States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedNasal Decolonization of Staphylococcus AureusSweden
-
Taro Pharmaceuticals USACompleted
-
Badr UniversityCompletedPressure Ulcers | Phonophoresis | Bee VenomEgypt